What is MS Pharma?
MS Pharma is a multinational pharmaceutical company specializing in the development, manufacturing, and distribution of generic and specialty medicines. With a robust presence across the Middle East and Africa, the company leverages its manufacturing facilities, R&D centers, and diverse product portfolio to enhance access to high-quality, affordable medications. MS Pharma is committed to strengthening pharmaceutical availability and patient care through strategic collaborations with healthcare systems and partners.
How much funding has MS Pharma raised?
MS Pharma has raised a total of $75M across 2 funding rounds:
Debt
$30M
Private Equity
$45M
Debt (2015): $30M with participation from European Bank for Reconstruction and Development
Private Equity (2017): $45M led by International Finance Corporation
Key Investors in MS Pharma
International Finance Corporation
The International Finance Corporation is a multilateral financial institution focused on mobilizing capital and expertise for sustainable development in emerging markets, providing financial solutions and advisory services to support private sector growth.
European Bank for Reconstruction and Development
The European Bank for Reconstruction and Development (EBRD) is a multilateral bank dedicated to fostering market-oriented economies and promoting private and entrepreneurial initiatives in its countries of operation.
What's next for MS Pharma?
The substantial enterprise-level backing positions MS Pharma for significant expansion and strategic initiatives. This infusion of capital is likely to fuel further research and development, enhance manufacturing capabilities, and broaden its market reach within the Middle East and Africa. The company's focus on generic and specialty medicines, coupled with its commitment to affordability and accessibility, suggests a strategic direction aimed at capturing greater market share and solidifying its role as a key regional healthcare player. Future growth may involve strategic acquisitions or partnerships to expand its therapeutic areas and geographical footprint.
See full MS Pharma company page
